Jenburkt Pharmaceuticals Ltd.

Financial

	Jenburkt Pharma	Albert David	Medicamen Biotech
Operational Metrics
Pharmaceutical Sector
R&D as a % of Total Sales	0.29 %	0.84 %	n/a
Financials
5 yr Average ROE	18.49 %	11.47 %	8.49 %
5yr average Equity Multiplier	1.17	1.63	1.47
5yr Average Asset Turnover Ratio	0.88	0.62	0.58
5yr Avg Net Profit Margin	18.1 %	11.31 %	10.0 %
Price to Book	2.84	1.17	2.13
P/E	15.06	72.72	47.66
5yr Avg Cash Conversion Cycle	-32.02 Days	-77.77 Days	13.14 Days
Inventory Days	24.72 Days	47.91 Days	84.58 Days
Days Receivable	48.38 Days	27.87 Days	139.4 Days
Days Payable	82.6 Days	140.35 Days	264.75 Days
5yr Average Interest Coverage Ratio	87.2	93.73	7.03
5yr Avg ROCE	24.44 %	14.69 %	12.12 %
5yr Avg Operating Profit Margin	22.46 %	9.55 %	16.84 %
5 yr average Debt to Equity	0.02	0.02	0.14
5yr CAGR Net Profit	14.21 %	-4.92 %	-11.57 %
5yr Average Return on Assets	15.8 %	7.03 %	5.75 %
Shareholdings
Promoter Holding	46.67 %	62.24 %	40.46 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.94 %	0.25 %	-3.14 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

Business

	Jenburkt Pharma	Albert David	Medicamen Biotech
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Dermatology 0 Pharmaceuticals Formulations 0	Product Wise Break-Up Pharmaceutical 0 Pharmaceuticals Formulations 0 Dermatology 0 Others 100	Product Wise Break-Up Pharmaceutical 0 Pharmaceuticals Formulations 100.0 Dermatology 0
Location Wise Break-Up	Location Wise Break-Up India 87.23 Rest of the World 12.56 Others 0.21	Location Wise Break-Up Rest of the World 6.76 India 93.24	Location Wise Break-Up Rest of the World 0 India 20.0 Others 80.0